

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**Form 10-Q**

---

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended June 30, 2019**

**OR**

**TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from            to**

**Commission file number: 1-33818**

---

**RESHAPE LIFESCIENCES INC.**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation)

**48-1293684**  
(IRS Employer  
Identification No.)

**1001 Calle Amanecer, San Clemente, California 92673**

(Address of principal executive offices, including zip code)

**(949) 429-6680**

(Registrant's telephone number, including area code)

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	<input type="checkbox"/>	Accelerated Filer	<input type="checkbox"/>
Non-accelerated filer	<input checked="" type="checkbox"/>	Smaller Reporting Company	<input checked="" type="checkbox"/>
Emerging Growth Company	<input type="checkbox"/>		

If an emerging growth company, indicate by check mark whether the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

**Securities registered pursuant to Section 12(b) of the Act:**

Title of Class	Trading Symbol	Name of Exchange on which Registered
Common stock, \$0.01 par value per share	RSLS	OTCQB Market

As of August 12, 2019, 30,605,233 shares of the registrant's Common Stock were outstanding.

---

---

**INDEX**

**PART I – FINANCIAL INFORMATION**

<a href="#">Item 1.</a>	<a href="#">Condensed Consolidated Financial Statements (unaudited)</a>	3
	<a href="#">Condensed Consolidated Balance Sheets at June 30, 2019 and December 31, 2018</a>	3
	<a href="#">Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2019 and 2018</a>	4
	<a href="#">Condensed Consolidated Statements of Stockholders' Equity for the three and six months ended June 30, 2019 and 2018</a>	5
	<a href="#">Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2019 and 2018</a>	7
	<a href="#">Notes to Condensed Consolidated Financial Statements</a>	8
<a href="#">Item 2.</a>	<a href="#">Management's Discussion and Analysis of Financial Condition and Results of Operations</a>	19
<a href="#">Item 4.</a>	<a href="#">Controls and Procedures</a>	24

**PART II – OTHER INFORMATION**

<a href="#">Item 1.</a>	<a href="#">Legal Proceedings</a>	25
<a href="#">Item 1A.</a>	<a href="#">Risk Factors</a>	26
<a href="#">Item 2.</a>	<a href="#">Unregistered Sales of Equity Securities and Use of Proceeds</a>	26
<a href="#">Item 3.</a>	<a href="#">Defaults Upon Senior Securities</a>	26
<a href="#">Item 4.</a>	<a href="#">Mine Safety Disclosures</a>	26
<a href="#">Item 5.</a>	<a href="#">Other Information</a>	26
<a href="#">Item 6.</a>	<a href="#">Exhibits</a>	26
	<a href="#">SIGNATURES</a>	28

**PART I – FINANCIAL INFORMATION****ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**RESHAPE LIFESCIENCES INC.**  
**Condensed Consolidated Balance Sheets**  
(dollars in thousands, except per share amounts; unaudited)

	June 30, 2019	December 31, 2018
<b>ASSETS</b>		
Current assets:		
Cash and cash equivalents	\$ 4,355	\$ 5,548
Accounts and other receivables (net of allowance for bad debts of \$387 at June 30, 2019 and \$236 at December 31, 2018) (Note 4)	4,625	917
Finished goods inventory	1,348	985
Prepaid expenses and other current assets (Note 4)	2,303	1,269
Total current assets	12,631	8,719
Property and equipment, net	27	64
Operating lease right-of-use assets (Note 7)	963	—
Other intangible assets, net (Note 5)	29,506	36,927
Other assets	563	563
Total assets	\$ 43,690	\$ 46,273
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>		
Current liabilities:		
Accounts payable and accrued liabilities (Note 4)	\$ 9,853	\$ 6,456
Asset purchase consideration payable, current (Note 6)	1,955	1,907
Operating lease liabilities, current (Note 7)	343	—
Total current liabilities	12,151	8,363
Asset purchase consideration payable, noncurrent (Note 6)	4,520	4,403
Operating lease liabilities, noncurrent (Note 7)	626	—
Deferred income taxes	1,258	1,844
Common stock warrant liability (Note 8)	11,743	—
Total liabilities	30,298	14,610
Commitments and contingencies (Note 13)		
Stockholders' equity:		
Preferred stock, 5,000,000 shares authorized:		
Series B convertible preferred stock, \$0.01 par value; 3 and 159 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively	—	—
Series C convertible preferred stock, \$0.01 par value; 95,388 shares issued and outstanding at June 30, 2019 and December 31, 2018	1	1
Common stock, \$0.01 par value; 275,000,000 shares authorized at June 30, 2019 and December 31, 2018; 28,505,233 and 8,770,433 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively	285	88
Additional paid-in capital	452,492	450,564
Accumulated deficit	(439,386)	(418,990)
Total stockholders' equity	13,392	31,663
Total liabilities and stockholders' equity	\$ 43,690	\$ 46,273

See accompanying notes to Condensed Consolidated Financial Statements.

**RESHAPE LIFESCIENCES INC.**  
**Condensed Consolidated Statements of Operations**  
(dollars in thousands, except per share amounts; unaudited)

	<u>Three Months Ended June 30,</u>		<u>Six Months Ended June 30,</u>	
	<u>2019</u>	<u>2018</u>	<u>2019</u>	<u>2018</u>
Revenue	\$ 4,450	\$ 10	\$ 7,524	\$ 149
Cost of revenue	1,593	3	2,436	63
Gross profit	2,857	7	5,088	86
<b>Operating expenses:</b>				
Selling, general and administrative	6,792	4,327	12,213	10,663
Research and development	960	2,053	2,016	4,553
Impairment of intangible assets (Note 5)	6,588	14,005	6,588	14,005
Total operating expenses	14,340	20,385	20,817	29,221
Operating loss	(11,483)	(20,378)	(15,729)	(29,135)
<b>Other expense (income), net:</b>				
Interest expense, net	213	1	316	2
Loss on extinguishment of debt (Note 6)	71	—	71	—
Warrant expense (Note 8)	4,127	145	4,257	145
Other, net	612	(3)	609	(2)
Loss from continuing operations before income taxes	(16,506)	(20,521)	(20,982)	(29,280)
Income tax benefit	586	1,209	586	2,591
Loss from continuing operations	(15,920)	(19,312)	(20,396)	(26,689)
Loss from discontinued operations, net of tax	—	(15,939)	—	(19,795)
Net loss	\$ (15,920)	\$ (35,251)	\$ (20,396)	\$ (46,484)
Less: Down round adjustments for convertible preferred stock and warrants	—	(3,842)	—	(3,842)
Net loss attributable to common shareholders	(15,920)	(39,093)	(20,396)	(50,326)
<b>Net loss per share - basic and diluted:</b>				
Continuing operations	(1.25)	(1,307.98)	\$ (1.94)	\$ (1,881.15)
Discontinued operations	—	(900.41)	—	(1,219.65)
Net loss per share - basic and diluted	\$ (1.25)	\$ (2,208.39)	\$ (1.94)	\$ (3,100.80)
Shares used to compute basic and diluted net loss per share	12,715,277	17,702	10,491,220	16,230

See accompanying notes to Condensed Consolidated Financial Statements.

**RESHAPE LIFESCIENCES INC.**  
**Condensed Consolidated Statements of Stockholders' Equity**  
**(dollars in thousands; unaudited)**

	Three Months Ended June 30, 2019										
	Series B Convertible Preferred Stock		Series C Convertible Preferred Stock		Series E Convertible Preferred Stock		Common Stock		Additional Paid-in Capital	Accumulated Deficit	Total Stockholders' Equity
	Shares	Amount	Shares	Amount	Shares	Amount	Shares	Amount			
<b>Balance March 31, 2019</b>	3	\$ —	95,388	\$ 1	1,192,000	\$ 12	7,703,233	\$ 77	\$451,949	\$ (423,466)	\$ 28,573
Net loss	—	—	—	—	—	—	—	—	—	(15,920)	(15,920)
Stock-based compensation expense	—	—	—	—	—	—	—	—	728	—	728
Down round adjustments for convertible preferred stock and warrants	—	—	—	—	—	—	—	—	—	—	—
Institutional sales of common stock and warrants, net of issuance costs	—	—	—	—	—	—	15,600,000	156	127	—	283
Warrant adjustment	—	—	—	—	—	—	—	—	(312)	—	(312)
Conversion of convertible preferred stock into common stock	—	—	—	—	(1,192,000)	(12)	1,192,000	12	—	—	—
Issuance of common stock upon exercise of warrants	—	—	—	—	—	—	4,010,000	40	—	—	40
<b>Balance June 30, 2019</b>	<b>3</b>	<b>\$ —</b>	<b>95,388</b>	<b>\$ 1</b>	<b>—</b>	<b>\$ —</b>	<b>28,505,233</b>	<b>\$ 285</b>	<b>\$452,492</b>	<b>\$ (439,386)</b>	<b>\$ 13,392</b>

	Six Months Ended June 30, 2019										
	Series B Convertible Preferred Stock		Series C Convertible Preferred Stock		Series E Convertible Preferred Stock		Common Stock		Additional Paid-in Capital	Accumulated Deficit	Total Stockholders' Equity
	Shares	Amount	Shares	Amount	Shares	Amount	Shares	Amount			
<b>Balance December 31, 2018</b>	159	\$ —	95,388	\$ 1	—	\$ —	8,770,433	\$ 88	\$450,564	\$ (418,990)	\$ 31,663
Net loss	—	—	—	—	—	—	—	—	—	(20,396)	(20,396)
Stock-based compensation expense	—	—	—	—	—	—	—	—	1,984	—	1,984
Warrant expense	—	—	—	—	—	—	—	—	130	—	130
Down round adjustments for convertible preferred stock and warrants	—	—	—	—	—	—	—	—	—	—	—
Institutional sales of common stock and warrants, net of issuance and other costs	—	—	—	—	—	—	15,600,000	156	127	—	283
Warrant adjustment	—	—	—	—	—	—	—	—	(312)	—	(312)
Conversion of common stock into convertible preferred stock	—	—	—	—	1,192,000	12	(1,192,000)	(12)	—	—	—
Conversion of convertible preferred stock into common stock	(156)	—	—	—	(1,192,000)	(12)	1,316,800	13	(1)	—	—
Issuance of common stock upon exercise of warrants, net of transaction costs	—	—	—	—	—	—	4,010,000	40	—	—	40
<b>Balance June 30, 2019</b>	<b>3</b>	<b>\$ —</b>	<b>95,388</b>	<b>\$ 1</b>	<b>—</b>	<b>\$ —</b>	<b>28,505,233</b>	<b>\$ 285</b>	<b>\$452,492</b>	<b>\$ (439,386)</b>	<b>\$ 13,392</b>

See accompanying notes to Condensed Consolidated Financial Statements.

**RESHAPE LIFESCIENCES INC.**  
**Condensed Consolidated Statements of Stockholders' Equity (Continued)**  
(dollars in thousands; unaudited)

	Three Months Ended June 30, 2018										
	Series B Convertible Preferred Stock		Series C Convertible Preferred Stock		Series D Convertible Preferred Stock		Common Stock		Additional Paid-in Capital	Accumulated Deficit	Total Stockholders' Equity
	Shares	Amount	Shares	Amount	Shares	Amount	Shares	Amount			
	6,055	—	95,388	1	—	—	14,742	—	411,865	(345,992)	65,874
<b>Balance March 31, 2018</b>											
Net loss	—	—	—	—	—	—	—	—	—	(35,251)	(35,251)
Stock-based compensation expense	—	—	—	—	—	—	—	—	810	—	810
Down round adjustments for convertible preferred stock and warrants	—	—	—	—	—	—	—	—	3,842	(3,842)	—
Institutional sale of convertible preferred stock and warrants in April 2018, net of issuance costs	—	—	—	—	6,000	—	—	—	5,081	—	5,081
Institutional sales of common stock and warrants, net of issuance costs	—	—	—	—	—	—	6,030	—	2,501	—	2,501
Redemption of convertible preferred stock	—	—	—	—	(500)	—	—	—	(500)	—	(500)
Conversions of convertible preferred stock into common stock	(3,098)	—	—	—	(750)	—	4,267	—	—	—	—
Issuance of common stock upon exercise of warrants, net of transaction costs	—	—	—	—	—	—	750	—	595	—	595
<b>Balance June 30, 2018</b>	<u>2,957</u>	<u>\$ —</u>	<u>95,388</u>	<u>\$ 1</u>	<u>4,750</u>	<u>\$ —</u>	<u>25,789</u>	<u>\$ —</u>	<u>\$ 424,194</u>	<u>\$ (385,085)</u>	<u>\$ 39,110</u>

	Six Months Ended June 30, 2018										
	Series B Convertible Preferred Stock		Series C Convertible Preferred Stock		Series D Convertible Preferred Stock		Common Stock		Additional Paid-in Capital	Accumulated Deficit	Total Stockholders' Equity
	Shares	Amount	Shares	Amount	Shares	Amount	Shares	Amount			
	6,055	\$ —	95,388	\$ 1	—	\$ —	14,742	\$ —	\$ 411,125	\$ (334,759)	\$ 76,367
<b>Balance December 31, 2017</b>											
Net loss	—	—	—	—	—	—	—	—	—	(46,484)	(46,484)
Stock-based compensation expense	—	—	—	—	—	—	—	—	1,550	—	1,550
Down round adjustments for convertible preferred stock and warrants	—	—	—	—	—	—	—	—	3,842	(3,842)	—
Institutional sale of convertible preferred stock and warrants in April 2018, net of issuance costs	—	—	—	—	6,000	—	—	—	5,081	—	5,081
Institutional sales of common stock and warrants, net of issuance costs	—	—	—	—	—	—	6,030	—	2,501	—	2,501
Redemption of convertible preferred stock	—	—	—	—	(500)	—	—	—	(500)	—	(500)
Conversions of convertible preferred stock into common stock	(3,098)	—	—	—	(750)	—	4,267	—	—	—	—
Issuance of common stock upon exercise of warrants, net of transaction costs	—	—	—	—	—	—	750	—	595	—	595
<b>Balance June 30, 2018</b>	<u>2,957</u>	<u>\$ —</u>	<u>95,388</u>	<u>\$ 1</u>	<u>4,750</u>	<u>\$ —</u>	<u>25,789</u>	<u>\$ —</u>	<u>\$ 424,194</u>	<u>\$ (385,085)</u>	<u>\$ 39,110</u>

See accompanying Notes to Condensed Consolidated Financial Statements.

**RESHAPE LIFESCIENCES INC.**  
**Condensed Consolidated Statements of Cash Flows**  
(dollars in thousands; unaudited)

	<b>Six Months Ended June 30,</b>	
	<b>2019</b>	<b>2018</b>
<b>Cash flows from operating activities:</b>		
Net loss	\$ (20,396)	\$ (46,484)
Loss from discontinued operations, net of tax	—	19,795
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation expense	30	145
Amortization of intangible assets	833	67
Impairment of intangible assets	6,588	14,005
Noncash interest expense	797	—
Fair value adjustment to embedded derivative	(481)	—
Loss on extinguishment of debt	71	—
Stock-based compensation	1,983	1,550
Warrant expense	4,257	145
Deferred income tax benefit	(586)	(2,591)
Other noncash items	14	—
Change in operating assets and liabilities:		
Accounts and other receivables	(3,709)	43
Inventory	(363)	348
Prepaid expenses and other current assets	(1,034)	(452)
Other assets	—	880
Accounts payable and accrued liabilities	3,397	1,656
<b>Net cash used in operating activities - continuing operations</b>	<b>(8,599)</b>	<b>(10,893)</b>
<b>Net cash used in operating activities - discontinued operations</b>	<b>—</b>	<b>(4,931)</b>
<b>Net cash used in operating activities</b>	<b>(8,599)</b>	<b>(15,824)</b>
<b>Cash flows from investing activities:</b>		
Purchases of property and equipment	—	(7)
<b>Net cash used in investing activities - continuing operations</b>	<b>—</b>	<b>(7)</b>
<b>Net cash used in investing activities</b>	<b>—</b>	<b>(7)</b>
<b>Cash flows from financing activities:</b>		
Proceeds from issuance of subordinated convertible debentures	2,000	—
Payments of debt financing costs	(21)	—
Repayment of subordinated convertible debentures	(2,200)	—
Proceeds from warrants exercised	40	488
Proceeds from sale and issuance of equity securities	7,616	9,004
Payments of equity issuance costs	(29)	(1,461)
Preferred stock redemption	—	(500)
<b>Net cash provided by financing activities - continuing operations</b>	<b>7,406</b>	<b>7,531</b>
<b>Net cash provided by financing activities</b>	<b>7,406</b>	<b>7,531</b>
<b>Net decrease in cash and cash equivalents</b>	<b>(1,193)</b>	<b>(8,300)</b>
<b>Cash and cash equivalents at beginning of period</b>	<b>5,548</b>	<b>10,163</b>
<b>Cash and cash equivalents at end of period</b>	<b>4,355</b>	<b>1,863</b>
<b>Noncash investing and financing activities:</b>		
Down round adjustment for convertible preferred stock and warrants	\$ —	\$ 3,842
Conversion of common stock to convertible preferred stock	(1)	—
Conversion of convertible preferred shares to common stock	—	—

See accompanying notes to Condensed Consolidated Financial Statements.

**ReShape Lifesciences Inc.****Notes to Condensed Consolidated Financial Statements****(dollars in thousands, except per share amounts; unaudited)****(1) Basis of Presentation**

The accompanying interim condensed consolidated financial statements and related disclosures of Reshape Lifesciences Inc. (the "Company") have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC") and should be read in conjunction with the consolidated financial statements and notes included in the Company's Annual Report on Form 10-K for the year ended December 31, 2018. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") have been condensed or omitted.

In the opinion of management, the interim consolidated condensed financial statements reflect all adjustments considered necessary for a fair statement of the interim periods. All such adjustments are of a normal, recurring nature. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year.

***Fair Value of Financial Instruments***

The carrying amounts of cash equivalents, accounts receivable, accounts payable and certain accrued and other liabilities approximate fair value due to their short-term maturities. Refer to Note 5 regarding the fair value of debt instruments and Note 8 regarding fair value measurements and inputs.

***Net Loss Per Share***

The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented:

	<b>June 30,</b>	
	<b>2019</b>	<b>2018</b>
Stock options	4,103	4,365
Convertible preferred stock	154,543	22,474
Warrants	242,709,036	28,438

The potential shares of common stock at June 30, 2019 exclude 980,969,318 of warrants issued in June 2019 that, pursuant to the terms of the warrant agreements, are not exercisable until the Company effects a reverse stock split.

***Recent Accounting Pronouncements***

New accounting standards adopted by the Company in 2019 are discussed below or in the related notes, where appropriate.

In February 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-02 *Leases (Topic 842)* that amended the guidance on leases. The amendment improves transparency and comparability among companies by recognizing lease assets and lease liabilities on the balance sheet and by disclosing key information about leasing arrangements. The guidance was effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Reporting entities could elect to adjust comparative periods and record the cumulative effect adjustment at the beginning of the earliest comparative period, or to not adjust comparative periods and record the cumulative effect adjustment at the effective date.

The Company adopted the new guidance as of the effective date of January 1, 2019 using the modified retrospective approach with no adjustments to the comparative period presented in the financial statements. In addition, the Company elected the package of practical expedients permitted under the transition guidance to not reassess (1)

whether any expired or existing contracts are, or contain, leases, (2) the lease classification for expired or existing leases, and (3) initial direct costs for existing leases.

The adoption of the guidance resulted in the recognition of right-of-use ("ROU") assets and lease liabilities for operating leases of \$1,176 as of January 1, 2019. The guidance did not have an impact on the Company's Condensed Consolidated Statements of Operations or Cash Flows. See Note 6 for disclosures related to the Company's leases.

In June 2018, the FASB issued ASU No. 2018-07, *Compensation – Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting*, which is intended to simplify the accounting for nonemployee share-based payment transactions by expanding the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The guidance was effective for fiscal years and interim periods within those years beginning after December 15, 2018, with early adoption permitted. The Company adopted this guidance effective January 1, 2019. The adoption of this guidance had no effect on the Company's consolidated financial statements as there were no share-based payment transactions with nonemployees in 2018 and such transactions in prior years, all of which had an established measurement date, were not material.

New accounting standards not yet adopted are discussed below.

In August 2018, the FASB issued ASU No. 2018-13, *Fair Value Measurement (Topic 820) – Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement*, which modifies the disclosure requirements on fair value measurements and is intended to improve the effectiveness of disclosures, including the consideration of costs and benefits. The guidance is effective for the fiscal years and interim periods within those years beginning after January 1, 2020. Early adoption is permitted, and an entity is permitted to early adopt any removed or modified disclosures and delay adoption of additional disclosures until their effective date. The Company is evaluating the effects of ASU 2018-13 on its consolidated financial statements.

In August 2018, the FASB issued ASU 2018-15, *Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract*. The amendments in this update align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The ASU is effective for the Company on January 1, 2020. Early adoption of the ASU is permitted. The Company is evaluating the effects of ASU 2018-15 on its consolidated financial statements.

In June 2016, the FASB issued ASU 2016-13, *Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments*, which is intended to provide financial statement users with more useful information about expected credit losses on financial assets held by a reporting entity at each reporting date. In May 2019, the FASB issued ASU No. 2019-05, which amended the new standard by providing targeted transition relief. The new guidance replaces the existing incurred loss impairment methodology with a methodology that requires consideration of a broader range of reasonable and supportable forward-looking information to estimate all expected credit losses. This guidance is effective for the fiscal years and interim periods within those years beginning after December 15, 2019 and early adoption is permitted for fiscal years and interim periods within those years beginning after December 15, 2018. The Company is currently evaluating the effects of ASU 2016-13 on its consolidated financial statements.

## **(2) Liquidity and Management's Plans**

The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company currently does not generate revenue sufficient to offset operating costs and anticipates such shortfalls to continue in the short-term to mid-term. The Company's history of operating losses and limited cash resources raise substantial doubt about its ability to continue as a going concern. As of June 30, 2019, the Company had \$4,355 of cash and cash equivalents.

The Company's anticipated operations include plans to (i) continue to integrate the sales and operations of the Company with the Lap-Band product line acquired in December 2018; (ii) continue development of the ReShape Vest, (iii) seek opportunities to leverage the Company's intellectual property portfolio and custom development services to

provide third party sales and licensing opportunities, and (iv) explore and capitalize on synergistic opportunities to expand our portfolio and offer future minimally invasive treatments and therapies in the obesity continuum of care. The Company believes that it has the flexibility to manage the growth of its expenditures and operations depending on the amount of available cash flows, which could include reducing expenditures for marketing, clinical and product development activities. However, the Company will ultimately need to achieve sufficient revenues from product sales and obtain additional equity or debt financing to support its operations.

Management is currently pursuing various funding options, including seeking additional equity or debt financing as well as a strategic merger or other transaction to obtain additional funding to support the expansion of Lap-Band product sales and to continue the development of, and to successfully commercialize, the ReShape Vest. While the acquisition of the Lap-Band product line does provide incremental revenues and cash flows to the Company, the cost to support the clinical trials of the ReShape Vest is expected to exceed internally generated cash flows for the foreseeable future. While there can be no assurance that the Company will be successful in its efforts, the Company has a long history of raising equity financing to fund its development activities. Should the Company be unable to obtain adequate financing in the near term, the Company's business, result of operations, liquidity and financial condition would be materially and negatively affected, and the Company would be unable to continue as a going concern. Additionally, there can be no assurance that, assuming the Company is able to strengthen its cash position, it will achieve sufficient revenue or profitable operations to continue as a going concern.

### (3) Discontinued Operations

During the fourth quarter of 2018, the Company sold substantially all of the assets exclusively related to its ReShape Balloon product line, which consisted of inventory, property and equipment and the related intellectual property underlying the intangible assets. The operating results of the ReShape Balloon product line have been reflected as discontinued operations in the Condensed Consolidated Financial Statements. In addition, the cash flows associated with discontinued operations are presented separately in the accompanying Condensed Consolidated Statements of Cash Flows.

There were no assets associated with the ReShape Balloon product line at June 30, 2019 and December 31, 2018. As described in Note 4 of the Company's Consolidated Financial Statements included in its Annual Report on Form 10-K for the year ended December 31, 2018, the Company recorded an impairment charge of \$13,182 in the second quarter of 2018 for the full write-down of the goodwill that had been recorded in connection with its acquisition in October 2017 of ReShape Medical, Inc. ("ReShape Medical"). The ReShape Balloon product line was the primary operating activity of ReShape Medical. The components of loss from discontinued operations for the three and six months ended June 30, 2018 consisted of the following:

	Three Months Ended	Six Months Ended
	June 30, 2018	
Revenue	\$ 644	\$ 1,455
Loss from discontinued operations before income taxes	(15,939)	(19,795)
Income tax benefit	—	—
Loss from discontinued operations, net of tax	\$ (15,939)	\$ (19,795)

### (4) Supplemental Balance Sheet Information

Components of selected captions in the condensed consolidated balance sheets consisted of the following:

#### *Accounts and other receivables, net:*

	June 30, 2019	December 31, 2018
Accounts receivable	\$ 2,209	\$ 510
Receivables, Apollo	2,416	407
Total accounts and other receivables	\$ 4,625	\$ 917

**Prepaid expenses and other current assets:**

	June 30, 2019	December 31, 2018
Prepaid contract research organization expenses	\$ 1,454	\$ 1,064
Prepaid insurance	659	58
Other current assets	190	147
Total prepaid expenses and other current assets	<u>\$ 2,303</u>	<u>\$ 1,269</u>

**Accounts payable and accrued liabilities:**

	June 30, 2019	December 31, 2018
Accounts payable	\$ 3,309	\$ 1,558
Payables, Apollo	928	69
Professional service related expenses	3,380	3,095
Payroll related expenses	1,490	1,146
Other accrued liabilities	746	588
Total accounts payable and accrued liabilities	<u>\$ 9,853</u>	<u>\$ 6,456</u>

In connection with the Company's December 2018 acquisition of the Lap-Band product line from Apollo Endosurgery, Inc. ("Apollo"), the Company entered into transition services, supply and distribution agreements with Apollo. The receivables from, and payables to, Apollo are primarily related to services performed under these agreements. During the second quarter of 2019, the invoicing and collection of Lap-Band orders from customers in the United States and Canada were transitioned to the Company. Apollo will continue to serve as the Company's distributor of Lap-Band product in certain other geographical areas outside the United States for up to one year from the acquisition date. In addition, for a period of up to 24 months from the acquisition date, Apollo issues purchase orders and procures certain accessory Lap-Band products from third-party suppliers on the Company's behalf. Remittances from and to Apollo are subject to a reconciliation of the credits/charges for services performed under the agreements.

**(5) Impairment of Intangible Assets****Second Quarter 2019**

Indefinite-lived intangible assets consist of in-process research and development ("IPR&D") for the ReShape Vest recorded in connection with the Company's acquisition of BarioSurg, Inc. ("BarioSurg") in May 2017. The Company has completed the feasibility study for the ReShape Vest and began clinical trials in Europe in 2018. During the second quarter of 2019, the Company performed a qualitative impairment analysis of the IPR&D. Due to delays in the clinical trials experienced during the first six months of 2019, the Company revised its expectations of when revenues would commence for the ReShape Vest, thus reducing the projected near-term future net cash flows related to the ReShape Vest. As a result, the Company performed a quantitative impairment analysis of the IPR&D and recorded an impairment charge of \$6,588 for the excess of the carrying value over the estimated fair value. The fair value of the IPR&D was estimated using an income approach which included discounting the revised projected future net cash flows to their present value.

The Company also assessed the recoverability of finite-lived intangible assets and did not identify any impairment as a result the performance of this analysis.

**Second Quarter 2018**

As described in Note 8 of the Company's Consolidated Financial Statements included in its Annual Report on Form 10-K for the year ended December 31, 2018, subsequent to the Company's registered direct securities offering on

April 3, 2018, the price of the Company's common stock declined significantly. Management determined that this event was an indicator of potential impairment as the magnitude of the decline indicated that the net equity of the Company may be in excess of its fair market value and conducted an impairment analysis during the second quarter of 2018. As a result, the Company recorded an impairment charge of \$14,005 for the full write-down of the goodwill recorded in connection with its acquisition of BarioSurg. In addition, as described in Note 3, discontinued operations for the three and six months ended June 30, 2018 include a goodwill impairment charge for the full write-down of the goodwill recorded in connection with the Company's acquisition of ReShape Medical.

In conjunction with the Company's evaluation of goodwill for impairment in the second quarter of 2018, the Company performed a qualitative impairment analysis on indefinite-lived intangible assets other than goodwill, and assessed the recoverability of finite-lived intangible assets. The Company did not identify any impairments of such indefinite-lived or finite-lived intangible assets as a result the performance of these analyses.

## **(6) Debt**

### ***Asset Purchase Consideration Payable***

The asset purchase consideration payable related to the Company's December 2018 acquisition of the Lap-Band product line from Apollo was initially recorded at net present value using a discount rate of 5.1%. The asset purchase consideration payable is secured by a first security interest in substantially all of the Company's assets. At June 30, 2019, the aggregate carrying value of the current and noncurrent asset purchase consideration payable of \$6,475, as adjusted for accretion of interest, and due to the first security interest held by Apollo, approximates fair value.

### ***Convertible Subordinated Debentures***

On March 29, 2019, the Company completed a private placement with certain healthcare focused institutional investors for the sale of secured subordinated original issue discount convertible debentures ("debentures") for a purchase price of \$2,000. The debentures had a maturity of June 28, 2019 and a face amount of \$2,200, reflecting a 10% original issue discount. The Company recorded an additional debt discount and a derivative liability for the fair value of the bifurcated embedded conversion features discussed below. The initial carrying amount of the debentures was recorded net of discounts and deferred financing costs of \$1,498. The Company repaid the debentures on June 20, 2019 at their face amount of \$2,200 with proceeds from an equity financing which closed on June 18, 2019. In connection with the early repayment of the debentures, the Company recorded a loss on extinguishment of debt of \$71, which consisted of the unamortized debt discount and deferred financing costs.

The debentures contained a conversion feature that provided that, at any time after June 28, 2019, if the debentures had not been repaid, but subject to certain investor ownership limitations, the debentures were convertible into shares of common stock at a conversion price equal to the lesser of \$0.33 and 80% of the average of the lowest two volume weighted average prices of the Company's common stock during the 20 trading days prior to conversion. The Company analyzed the conversion features embedded in the debentures and determined that bifurcation and liability classification was required under ASC 815 due to the variable number of shares issuable upon conversion. The fair value of the bifurcated embedded conversion features was determined to be \$481 as of the issuance date using a Monte Carlo model and primarily Level 3 inputs. Upon the closing of the Company's equity financing and the Company's planned use of a portion of the proceeds to repay the debentures, the fair value of the embedded derivative liability was reduced to zero as the conversion feature was no longer available. The fair value adjustment to the embedded derivative liability of \$481 was recorded as a reduction to Interest Expense for the three and six months ended June 30, 2019.

In connection with the financing, the Company amended the exercise price of warrants to purchase up to 8 million shares of common stock held by the investors that were issued on November 28, 2018 from \$1.50 per share to \$0.01 per share. The value attributable to the exercise price reduction of \$130 was recorded in Warrant Expense for the six months ended June 30, 2019 and was estimated using the Black Scholes option pricing model using a risk-free interest rate of 2.2%, an expected term of 4.7 years, expected dividends of zero and expected volatility of 204.4%.

## **(7) Leases**

On the date of adoption of Topic 842, the Company had noncancelable operating leases for office and warehouse space in San Clemente, California and noncancelable operating leases for certain office equipment that expire at various

dates through 2022. The Company does not have any short-term leases or financing lease arrangements and there have been no lease modifications. Certain of the Company's equipment leases include variable lease payments that are adjusted periodically based on actual usage. Lease and non-lease components are accounted for separately.

Operating lease costs for the three and six months ended June 30, 2019 were \$121 and \$241, respectively. Variable lease costs were not material.

Supplemental information related to operating leases was as follows:

<b>Balance Sheet Information at June 30, 2019</b>	
Operating lease ROU assets	\$ 963
Operating lease liabilities, current portion	\$ 343
Operating lease liabilities, long-term portion	626
Total operating lease liabilities	\$ 969
<b>Cash Flow Information for the Six Months Ended June 30, 2019</b>	
Cash paid for amounts included in the measurement of operating leases liabilities	\$ 234

Maturities of operating lease liabilities at June 30, 2019 were as follows:

<b>Twelve months ending June 30,</b>	
2020	\$ 384
2021	328
2022	332
Total lease payments	1,044
Less: imputed interest	75
Total lease liabilities	\$ 969
Weighted-average remaining lease term at end of period (in years)	2.8
Weighted-average discount rate at end of period	5.1 %

***Disclosures related to periods prior to adopting the new lease guidance***

Future minimum lease commitments under noncancelable operating leases as of December 31, 2018 were as follows:

<b>Year ending December 31,</b>	
2019	\$ 449
2020	332
2021	331
2022	166
Total	\$ 1,278

**(8) Equity**

As described in Note 12 of the Company's Consolidated Financial Statements included in its Annual Report on Form 10-K for the year ended December 31, 2018, certain of the Company's issuances of convertible preferred stock and warrants contain non-standard down round features which result in adjustments to the conversion price of the preferred stock and exercise price of the warrants in the event of future stock sales at a lower unit price. As of June 30, 2019, warrants issued to investors in connection with the sale of convertible preferred stock in August 2017 and warrants issued to investors in connection with the sale of common stock in June, July and August 2018, as amended, contain

such down round features. At June 30, 2019, the exercise price of warrants with these down round features was \$0.02 per share, as last reset effective with a direct financing completed on June 18, 2019.

Down round adjustments were not material during the three and six months ended June 30, 2019. During the three and six months ended June 30, 2018, the Company recorded a total of \$3,842 of down round adjustments attributable to changes in the conversion price of convertible preferred stock and reductions in the exercise price of warrants. The value attributable to the warrant exercise price reductions in the three and six months ended June 30, 2018 was estimated using the Black Scholes model using risk-free interest rates ranging from 2.13% to 2.81%; expected lives ranging from less than one year to 6.2 years; expected dividends of zero and expected volatility ranging from 111.63% to 126.38%.

The Company had the following equity transactions during the six months ended June 30, 2019 and 2018:

#### ***June 2019 Issuance of Common Stock and Warrants***

On June 18, 2019, the Company completed a private placement with certain healthcare focused institutional investors for the sale of 15,600,000 shares of common stock at a purchase price of \$0.02 per share and series C prefunded warrants to purchase 384,400,000 shares of common stock at a purchase price of \$0.019 per share. The exercise price of each pre-funded warrant is \$0.001 per share. The Company also issued series A warrants to purchase 400,000,000 shares of common stock at an exercise price of \$0.020 per share and series B warrants to purchase 400,000,000 shares of common stock at an exercise price of \$0.022 per share. Net proceeds from the private placement were \$6,873 after deducting placement agent fees and other transaction costs. In connection with the registered direct offering, the placement agent received warrants to purchase 28,000,000 shares of common stock at an exercise price of \$0.025 per share. The warrants issued to the placement agent are not exercisable until after the Company effects a reverse stock split.

The prefunded series C and the series A and B warrants were exercisable upon the closing of the private placement; however, until the Company effects a reverse stock split, the number of warrants that may be exercised is limited to the number of available unissued authorized shares, as defined in the warrant agreements ("Issuable Maximum"). Because the warrant holders may elect to exercise any of the series C prefunded or series A and B warrants up to their pro rata share of the Issuable Maximum, the \$7,304 in gross proceeds from the sale of the series C prefunded warrants was recorded as a liability. As a result of the liability treatment of the prefunded warrants, the Company included \$714 of the transaction costs in Other, net in the Condensed Consolidated Statements of Operations.

The series A and B warrants, series C prefunded warrants and common stock issued contain variable price features until the Company effects a reverse stock split. As a result, the total number of the shares of common stock and series C prefunded warrants purchased and the exercise prices of the series A and B warrants are not fixed until after the Company effects a reverse stock split. The Company analyzed the variable price features and established a warrant liability at the issuance date of \$15,966. As the initial value of the warrant liability exceeded the proceeds received from the equity offering, the excess value of \$8,340 was recorded as Warrant Expense. The Company revalued the warrant liability at June 30, 2019 and recorded the decrease in fair value of \$4,213 as a reduction of Warrant Expense in the Condensed Consolidated Statements of Operations. The fair values of the warrant liability were determined using a Monte Carlo model and primarily Level 3 inputs.

#### ***February 2019 Conversion of Common Stock into New Series of Convertible Preferred Stock***

On February 1, 2019, pursuant to an exchange agreement with Sabby Volatility Warrant Master Fund, Ltd. ("Sabby") 1,192,000 shares of the Company's common stock were exchanged for an aggregate of 1,192,000 shares of series E convertible preferred stock, par value \$0.01 per share ("Series E Preferred Stock") in a noncash transaction. Each share of Series E Preferred Stock was convertible into one share of common stock at Sabby's election. In April 2019, all shares of Series E Preferred Stock were converted into an equal number of shares of common stock.

#### ***Conversion of Series B Convertible Preferred Stock into Common Stock***

During the six months ended June 30, 2019, 156 shares of Series B convertible preferred stock ("Series B Preferred Stock") were converted into 124,800 shares of common stock. At June 30, 2019, the remaining 3 shares of Series B Preferred stock are convertible into 150,000 shares of common stock.

### June 2018 Issuances of Common Stock and Warrants

On June 21, 2018, the Company completed a registered direct offering which included the sale of 3,354 shares of common stock at a purchase price of \$429.80 per share and warrants to purchase 3,354 shares of common stock at a purchase price of \$17.50 per share. The initial exercise price of each warrant was \$431.20 per share. In connection with the registered direct offering, the placement agent received warrants to purchase 163 shares of common stock at an exercise price of \$558.60 per share. Net proceeds from the registered direct offering were \$1,269, after deducting placement agent fees and other transaction costs. The Company used \$500 of the net proceeds of the offering to redeem 500 of the then currently 5,250 outstanding shares of its series D convertible preferred stock, which the Company agreed to as an inducement to obtain the required consent of the holder of series D convertible preferred stock for the Company to complete the offering.

On June 9, 2018, the Company completed a registered direct offering which included the sale of 2,676 shares of common stock at a purchase price of \$548.80 per share and warrants to purchase 2,007 shares of common stock at a purchase price of \$17.50 per share. The initial exercise price of each warrant was \$550.20 per share. In connection with the registered direct offering, the placement agent received warrants to purchase 188 shares of common stock at an exercise price of \$701.40 per share. Net proceeds from the registered direct offering were \$1,232, after deducting placement agent fees and other transaction costs.

### April 2018 Issuance of Convertible Preferred Stock and Warrants

On April 3, 2018 the Company completed a registered direct offering which included the sale of 6,000 shares of series D convertible preferred stock, par value \$0.01 per share (“Series D Preferred Stock”), at a purchase price of \$1,000 per share and warrants to purchase 16,667 shares of common stock at an initial exercise price of \$1,575 per share. Net proceeds from the registered direct offering were \$5,081, after deducting placement agent fees and other transaction costs. In April 2019, the remaining warrants to purchase 16,366 shares of common stock, net of the warrants exercised in May 2018 as discussed in Note 8, expired in accordance with their terms.

In addition to the shares of Series D Preferred Stock redeemed in connection with the registered direct offering completed on June 21, 2018, 750 shares of the Series D Preferred Stock were converted into 477 shares of common stock during the three and six months ended June 30, 2018.

### (9) Warrants

On May 24, 2018, an institutional investor agreed to exercise an aggregate of 751 warrants to purchase common stock in exchange for a reduction in the warrant exercise price. The warrant exercise was accounted for as a warrant inducement and the related fair value adjustment to the exercised warrants of \$146 was recorded in Warrant Expense in the Consolidated Statements of Operations for the three and six months ended June 30, 2018. The value attributable to the exercise price reductions was estimated using the Black Scholes option pricing model using risk-free interest rates ranging from 2.28% to 2.65%; expected terms ranging from less than one year to 3.7 years; expected dividends of zero and expected volatility ranging from 120.44% to 142.78%.

### (10) Revenue Disaggregation and Operating Segments

The following table presents the Company’s revenue disaggregated by product and geography:

	Three Months Ended June 30, 2019			Three Months Ended June 30, 2018		
	U.S.	OUS *	Total	U.S.	OUS	Total
Lap-Band product	\$ 4,010	\$ 440	\$ 4,450	\$ —	\$ —	\$ —
ReShape vBloc product	—	—	—	10	—	10
Total	\$ 4,010	\$ 440	\$ 4,450	\$ 10	\$ —	\$ 10

  

	Six Months Ended June 30, 2019			Six Months Ended June 30, 2018		
	U.S.	OUS *	Total	U.S.	OUS	Total
Lap-Band product	\$ 7,076	\$ 448	\$ 7,524	\$ —	\$ —	\$ —
ReShape vBloc product	—	—	—	149	—	149
Total	\$ 7,076	\$ 448	\$ 7,524	\$ 149	\$ —	\$ 149

\*The next largest individual country outside the U.S. was Australia, which was 9.5% and 5.6% of total revenues for the three months and six months ended June 30, 2019 and 2018, respectively.

As described in Note 4 of the Company's Consolidated Financial Statements included in its Annual Report on Form 10-K for the year ended December 31, 2018, the Company acquired the Lap-Band product line in December 2018. As a result of the acquisition of the Lap-Band product line, the Company is no longer actively marketing the ReShape vBloc product.

### ***Operating Segments***

The Company's operating segments currently consist of the Lap-Band segment and the ReShape Vest segment. These two operating segments are reported based on the financial information provided to the Chief Operating Decision Maker (the Chief Executive Officer, or "CODM"). The Company's CODM evaluates segment performance based on gross profit. The Company's CODM does not use operating segment assets information to allocate resources or to assess performance of the operating segments and thus total segment assets have not been disclosed

The Company acquired the established Lap-Band product line in December 2018, and the Lap-Band product line accounted for all of the Company's revenues and gross profit for the three and six months ended June 30, 2019. There were no revenues or gross profit recorded for the ReShape Vest operating segment for the three months and six months ended June 30, 2019 and 2018 because the ReShape Vest is still in the development stage.

The Company's CODM no longer evaluates performance related to ReShape vBloc, as revenues and gross profit during each of the three months ended June 30 and September 30, 2018 were insignificant, and there have been no revenues or gross profit associated with the ReShape vBloc product since September 30, 2018. In addition, the Company is no longer actively marketing the ReShape vBloc product.

### **(11) Income Taxes**

In connection with the impairment of IPR&D discussed in Note 5, which resulted in a reduction in the deferred tax liability associated with the indefinite-lived intangible asset, the Company recorded an income tax benefit of \$586 for the three and six months ended June 30, 2019. The income tax benefit is net of an increase to the deferred tax valuation allowance of \$1,052 for the portion of the deferred tax liability reversal that had been netted with the deferred tax asset associated with U.S. federal net operating loss carryforwards that do not expire.

The income tax benefit from continuing operations for the three and six months ended June 30, 2018 of \$1,209 and \$2,591, respectively, reflects the tax impact of the net operating losses from continuing operations generated in the periods which have an indefinite carryover period. A portion of these net operating losses were supported by expected taxable income from the reversal of indefinite-lived intangibles, such that they are more likely than not to be realized.

### **(12) Stock-based Compensation**

Stock-based compensation expense related to stock options issued under the ReShape Lifesciences Inc. Second Amended and Restated 2003 Stock Incentive Plan (the "Plan") and as inducement grants for the three and six months ended June 30, 2019 and 2018 was as follows:

	<b>Three Months Ended</b>		<b>Six Months Ended</b>	
	<b>June 30,</b>		<b>June 30,</b>	
	<b>2019</b>	<b>2018</b>	<b>2019</b>	<b>2018</b>
Selling, general and administrative	\$ 696	\$ 770	\$ 1,919	\$ 1,452
Research and development	31	40	64	98
<b>Total</b>	<b>\$ 727</b>	<b>\$ 810</b>	<b>\$ 1,983</b>	<b>\$ 1,550</b>

As of June 30, 2019, there was approximately \$4,120 of total unrecognized compensation costs related to unvested stock option awards, which are expected to be recognized over a weighted-average period of 2.3 years.

There were no stock options granted during the three and six months ended June 30, 2019. During the three and six months ended June 30, 2018, the Company granted 2,868 stock options under the Plan at a weighted average exercise price of \$1,336.72 per share. There were no stock options exercised during the three and six months ended June 30, 2019 and 2018.

The weighted-average assumptions used in the Black-Scholes option pricing model to estimate the grant date fair value of stock options granted during the three and six months ended June 30, 2018 were as follows:

Risk-free interest rate	2.85%
Expected term (in years)	6.25
Expected dividend yield	0%
Expected volatility	121.52%

The total estimated grant date fair value of stock options granted during the three and six months ended June 30, 2018 was \$3,468.

### **(13) Commitments and Contingencies**

#### ***Litigation***

*Fulfillium.* On April 20, 2017, Fulfillium, Inc. filed a complaint against ReShape Medical, Inc. (which the Company acquired in October 2017 and which is now a wholly owned subsidiary of the Company) in the U.S. District Court for the District of Delaware, which alleged misappropriation of trade secrets and infringement of two U.S. Patents (“Fulfillium I”). On July 28, 2017, ReShape Medical moved to dismiss both the trade secret claim and certain aspects of the patent infringement claim, and to transfer the litigation to the U.S. District Court for the Central District of California. On October 16, 2017, the Court granted ReShape Medical’s motion to dismiss the trade secret and willful infringement claims, and ordered the case transferred to the U.S. District Court for the Central District of California. Fulfillium twice amended its complaint, narrowing its original trade secret claim and adding further patent infringement claims and additional parties. On June 4, 2018, ReShape Medical filed a motion to dismiss the patent infringement claims for lack of standing, which the Court granted on July 5, 2018. On August 10, 2018, the Court dismissed without prejudice the trade secret claim for lack of subject matter jurisdiction and terminated the case. Fulfillium has appealed these dismissals and ReShape Medical has appealed the grant and denial of certain attorney fee awards. On July 20, 2018, Fulfillium filed a new complaint against ReShape Lifesciences, Inc. (and its wholly owned subsidiary ReShape Medical LLC) in the U.S. District Court for the Central District of California (“Fulfillium II”) reasserting the patent infringement claims asserted in Fulfillium I. On August 15, 2018, Fulfillium amended its complaint in Fulfillium II to reassert the trade secret misappropriation claim asserted in Fulfillium I against ReShape Medical LLC and others. On September 7, 2018, Fulfillium filed a complaint in California state court alleging the same trade secret misappropriation claim asserted in both Fulfillium I and Fulfillium II. On November 7, 2018, the Court dismissed the non-Company parties from Fulfillium II. On April 20, 2018, ReShape Medical filed Inter Partes Review (“IPR”) petitions with the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office (the “PTAB”) to have all claims of both of the originally asserted Fulfillium patents canceled as unpatentable over various combinations of prior art. On November 6, 2018, the PTAB denied those petitions. The parties held a mediation on April 9, 2019, but were unable to resolve the matter. The Company intends to continue to vigorously defend itself against Fulfillium’s claims. We currently are unable to estimate the losses or range of loss for these two matters.

*Alpha and Iroquois.* On July 12, 2018, Alpha Capital Anstalt (“Alpha”) filed a complaint against the Company in the U.S. District Court for the Southern District of New York. In August 2017, Alpha acquired shares of the Company’s series B convertible preferred stock and warrants to purchase shares of the Company’s common stock in an underwritten public offering. Pursuant to the terms of the series B convertible preferred stock and warrants, the conversion price of the series B convertible preferred stock and exercise price of the warrants was subject to adjustment in the case of, among other things, dilutive issuances of securities by the Company. The complaint alleged breach of contract, claiming that the Company should have adjusted the conversion price of the series B convertible preferred stock and exercise price of the warrants to not less than \$420.00 per share, rather than the \$1,575.00 per share to which the Company actually adjusted such conversion price and exercise price, in connection with its registered direct offering of series D convertible preferred stock and warrants to purchase common stock that it completed and announced in April 2018. On July 26, 2018, Iroquois Capital Investment Group, LLC and Iroquois Master Fund, Ltd. (“Iroquois”) filed a complaint against the Company in the U.S. District Court for the Southern District of New York, with substantially the same claims and

seeking substantially the same relief as Alpha's complaint described above, except that Iroquois claimed that the conversion price of the series D convertible preferred stock and exercise price of the warrants should have been adjusted to \$189.00 per share. Following a mediation held on June 20, 2019, the parties each entered into a mutually agreeable settlement agreement resolving the issues raised in the complaints filed by each Alpha and Iroquois. Pursuant to the settlement agreements, each lawsuit has been dismissed with prejudice. The terms of the settlement agreements are confidential.

Except as disclosed in the foregoing paragraphs, the Company is not currently a party to any litigation and the Company is not aware of any pending or threatened litigation against it that is reasonably possible to have a material adverse effect on the Company's business, operating results or financial condition. The medical device industry in which the Company operates is characterized by frequent claims and litigation, including claims regarding patent and other intellectual property rights as well as improper hiring practices. As a result, the Company may be involved in various legal proceedings from time to time.

***Product Liability Claims***

The Company is exposed to product liability claims that are inherent in the testing, production, marketing and sale of medical devices. Management believes any losses that may occur from these matters are adequately covered by insurance, and the ultimate outcome of these matters will not have a material effect on the Company's financial position or results of operations. The Company is not currently a party to any product liability litigation and is not aware of any pending or threatened product liability litigation that is reasonably possible to have a material adverse effect on the Company's business, operating results or financial condition.

## ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

*The following discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto appearing elsewhere in this Quarterly Report on Form 10-Q.*

*Except for the historical information contained herein, the matters discussed in this "Management's Discussion and Analysis of Financial Condition and Results of Operations," are forward-looking statements that involve risks and uncertainties. In some cases, these statements may be identified by terminology such as "may," "will," "should," "expects," "could," "intends," "might," "plans," "anticipates," "believes," "estimates," "predicts," "potential," or "continue," or the negative of such terms and other comparable terminology. These statements involve known and unknown risks and uncertainties that may cause our results, level of activity, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Factors that may cause or contribute to such differences include, among others, those discussed in the "Risk Factors" section included in Item 1A of our Annual Report on Form 10-K filed on May 16, 2019.*

*Except as may be required by law, we undertake no obligation to update any forward-looking statement to reflect events after the date of this report.*

### Overview

We are a developer of minimally invasive medical devices that advance bariatric surgery to treat obesity and metabolic diseases. Our current portfolio includes the LAP-BAND® Adjustable Gastric Banding System and the ReShape Vest™, an investigational device, to help treat more patients with obesity. There has been no revenue recorded for the ReShape Vest as the product is still in the development stage. Following our acquisition of the Lap-Band product line in December 2018, we are no longer actively marketing the ReShape vBloc product.

### Results of Operations

#### Continuing Operations

*Revenue.* Revenue for the three and six months ended June 30, 2019 of \$4.4 million and \$7.5 million, respectively, consisted of sales of our Lap-Band product which we acquired in December 2018. Revenues in the current quarter increased \$1.3 million over the first three months of 2019, which was primarily due to revenue growth of \$0.9 million in the U.S. over the previous quarter. In addition, as a result of our obtaining all distribution rights for the Lap-Band product in April 2019, we had \$0.4 million of revenues in Australia. For the three and six months ended June 30, 2018, revenue of \$0.1 million in each period was comprised of sales of our ReShape vBloc product.

*Gross profit.* Gross profit in the second quarter and first half of 2019 of \$2.9 million and \$5.1 million, respectively, reflects cost of sales associated with the established Lap-Band product line. Gross profit as a percentage of total revenue for the three and six months ended June 30, 2019 was 64 percent and 68 percent, respectively, as compared with 73 percent for the first three months of 2019. The lower gross profit rates in the second quarter and first half of 2019 are primarily the result of sales during the second quarter to a subsidiary of Apollo Endosurgery, Inc. ("Apollo"). Pursuant to a distribution agreement, Apollo serves as the Company's distributor of Lap-Band product in certain geographical areas outside the U.S. for a period of up to one year from the acquisition date of the Lap-Band product line. Gross profit on sales of the ReShape vBloc product in the second quarter and first half of 2018 was \$0.01 million in both periods.

*Selling, General and Administrative Expenses.* Selling, general and administrative expenses were \$6.8 million for the three months ended June 30, 2019 as compared with \$5.4 million for the three months ended March 31, 2019 and \$4.3 million for the three months ended June 30, 2018. For the six months ended June 30, 2019 and 2018, selling general and administrative expenses were \$12.2 million and \$10.7 million, respectively. Selling, general and administrative expenses in the second quarter and first half of 2019 include \$0.9 million of severance costs and \$0.5 million of one-time litigation related expenses. The remainder of the increase in 2019 over the same periods in 2018 is primarily the result of an increase in our selling costs due to the increase in sales personnel and higher commissions associated with the increased Lap-Band revenues.

*Research and Development Expenses.* Research and development expenses were \$1.0 million for the three months ended June 30, 2019 compared with \$2.1 million for the three months ended June 30, 2018. For the six months ended June 30, 2019, research and development expenses were \$2.0 million compared with \$4.6 million for the six months ended June 30, 2018. During the 2019, our research and development activities were limited to the continued development of the ReShape Vest. Research and development expenses for the 2018 periods included development activities for both the ReShape Vest and ReShape vBloc.

*Impairment of Intangible Assets.* As a result of an impairment analysis performed during the second quarter of 2019, we recorded an impairment charge of \$6.6 million on the indefinite-lived intangible asset recorded in connection with our acquisition of BarioSurg, Inc. (“BarioSurg”) in May 2017. We also assessed the recoverability of finite-lived intangible assets during the second quarter of 2019 and did not identify any impairment as a result the performance of this analysis. Based on an impairment analysis of our goodwill and intangible assets performed during the quarter ended June 30, 2018, we recorded an impairment loss of \$14.2 million for the three and six months ended June 30, 2018, eliminating all goodwill balances related to our acquisition of BarioSurg. There were no impairment charges recorded relative to the indefinite and finite-lived intangible assets in 2018. Refer to Note 5 to our Condensed Consolidated Financial statements for additional information about impairment of intangible assets.

*Net Interest Expense and Loss on Extinguishment of Debt.* We had net noncash interest expense of \$0.2 million and \$0.3 million for the three months and six months ended June 30, 2019. During the second quarter and first half of 2019, accretion of interest expense on the net present value of the asset purchase consideration payable and the discount and deferred financing costs on the convertible subordinated debentures totaled \$0.7 million and \$0.9 million, respectively. This noncash interest expense was reduced by \$0.5 million for the write-off of an embedded derivative liability recorded for the conversion features of the debentures that were eliminated as a result of the repayment of the debentures prior to their maturity date. In connection with the early repayment of the debentures, we recorded a loss on extinguishment of debt of \$0.1 million, which consisted of the unamortized debt discount and deferred financing costs. Refer to Note 6 to our Condensed Consolidated Financial statements for additional information about the asset purchase consideration payable and the convertible subordinated debentures.

*Warrants Expense.* Warrant expense for the three and six months ended June 30, 2019 includes noncash expense of \$8.3 million for the value of variable price features included with the warrants and common stock issued in connection with our equity financing completed in June 2019 in excess of the proceeds received. This noncash expense was reduced by \$4.2 million for the decrease in fair value of the warrant liability between the issuance date and June 30, 2019. In addition, during the six months ended June 30, 2019, we recorded warrant expense of \$0.1 million for the change in fair value of certain warrants held by certain institutional investors for which the exercise price was reduced in connection with the sale of convertible subordinated debentures to those investors. Warrant expense of \$0.1 million for the three and six months ended June 30, 2018 is primarily related to the change in fair value of certain warrants held by an institutional investor for which the exercise price was reduced as an inducement for the investor to exercise the warrants.

*Other, Net.* Other, net for the three and six months ended June 30, 2019 includes \$0.7 million of transaction costs required to be expensed as a result of the liability treatment for the warrants issued in connection with our June equity financing. See Note 8 to our Condensed Consolidated Financial statements for additional information about our June equity financing.

*Income tax benefit.* The income tax benefit of \$0.6 million for the three and six months ended June 30, 2019 is due to a reduction in the deferred tax liability associated with an indefinite-lived intangible asset, for which we recorded an impairment charge of \$6.6 million during the three months ended June 30, 2019. The income tax benefit is net of an increase to the deferred tax valuation allowance of \$1.1 million for the portion of the deferred tax liability reversal that had been netted with the deferred tax asset associated with U.S. federal net operating loss carryforwards that do not expire. The income tax benefit recorded for the three months and six ended June 30, 2018 of \$1.2 million and \$2.6 million, respectively, reflects the tax impact of the net operating loss in the period which have an indefinite carryover

period. A portion of these net operating losses were supported by expected taxable income from the reversal of indefinite-lived intangibles, such that they are more likely than not to be realized.

### ***Discontinued Operations***

Loss from discontinued operations for the three and six months ended June 30, 2018 of \$15.9 million and \$19.8 million, respectively, reflects the activities of our Reshape Balloon product line, which we sold in December 2018 in connection with our acquisition of the Lap-Band product line assets. The loss for the quarter and year to date periods includes an impairment charge of \$13.2 million for the full write-down of the goodwill recorded in connection with our acquisition of ReShape Medical, Inc. There was no income tax expense or benefit for discontinued operations.

### **Liquidity and Capital Resources**

As of June 30, 2019, we had \$4.4 million of cash and cash equivalents to fund operations. We have financed our operations to date principally through the sale of equity securities and debt financing. Our anticipated operations include plans to (i) continue to integrate the sales and operations of the Company with the newly acquired Lap-Band product line in order to expand sales domestically and internationally as well as to obtain cost savings synergies, (ii) continue development of the ReShape Vest, (iii) seek opportunities to leverage our intellectual property portfolio and custom development services to provide third party sales and licensing opportunities, and (iv) explore and capitalize on synergistic opportunities to expand our portfolio and offer future minimally invasive treatments and therapies in the obesity continuum of care. The Company believes that it has the flexibility to manage the growth of its expenditures and operations depending on the amount of available cash flows, which could include reducing expenditures for marketing, clinical and product development activities. However, the Company will ultimately need to achieve sufficient revenues from product sales and obtain additional debt or equity financing to support its operations.

Management is currently pursuing various funding options, including seeking additional equity or debt financing as well as a strategic merger or other transaction to obtain additional funding to support the expansion of Lap-Band product sales and to continue the development of, and to successfully commercialize, the ReShape Vest. While the acquisition of Lap-Band product line does provide incremental revenues and cash flows to the Company, the cost to support the clinical trials of the ReShape Vest is expected to exceed internally generated cash flows for the foreseeable future. While there can be no assurance that the Company will be successful in its efforts, the Company has a long history of raising equity financing to fund its development activities. Should the Company be unable to obtain adequate financing in the near term, the Company's business, result of operations, liquidity and financial condition would be materially and negatively affected, and the Company would be unable to continue as a going concern. Additionally, there can be no assurance that, assuming the Company is able to strengthen its cash position, it will achieve sufficient revenue or profitable operations to continue as a going concern.

#### ***Net Cash Used in Operating Activities - Continuing Operations***

Net cash used in operating activities from continuing operations was \$8.6 million and \$10.9 million for the six months ended June 30, 2019 and 2018, respectively. Net cash used in operating activities from continuing operations was primarily the result of the loss from continuing operations in each year net of noncash items and changes in operating assets and liabilities.

#### ***Net Cash Provided by Financing Activities from Continuing Operations***

Net cash provided by financing activities of \$7.4 million for the six months ended June 30, 2019 was primarily related to the \$7.6 million of cash proceeds we received in connection with an equity financing completed in June 2019. A portion of the net proceeds from the equity financing were used to repay the \$2.2 million face amount of convertible subordinated debentures that were issued at an original issue discount of 10 percent in March 2019.

### ***Discontinued Operations***

Net cash used in operating activities of discontinued operations of \$4.9 million for the six months ended June 30, 2018, reflects activities of the ReShape Balloon product line. There were no investing or financing activities related to discontinued operations for the six months ended June 30, 2018.

### ***Operating Capital and Capital Expenditure Requirements***

Our anticipated operations include plans to (i) continue to integrate the sales and operations of the Company with the newly acquired Lap-Band product line; (ii) continue development of the ReShape Vest, (iii) seek opportunities to leverage the Company's intellectual property portfolio and custom development services to provide third party sales and licensing opportunities, and (iv) explore and capitalize on synergistic opportunities to expand our portfolio and offer future minimally invasive treatments and therapies in the obesity continuum of care. The Company believes that it has the flexibility to manage the growth of its expenditures and operations depending on the amount of available cash flows, which could include reducing expenditures for marketing, clinical and product development activities. However, the Company will ultimately need to achieve sufficient revenues from product sales and obtain additional equity or debt financing to support its operations.

Obtaining funds through the sale of additional equity and debt securities or the warrant holders' exercise of outstanding common stock warrants may result in dilution to our stockholders. If we raise additional funds through the issuance of debt securities, these securities could have rights senior to those of our common stock and could contain covenants that would restrict our operations. The sale of additional equity may require us to obtain approval from our stockholders to increase the number of shares of common stock we have authorized under our certificate of incorporation. We may require additional capital beyond our currently forecasted amounts. Any such required additional capital may not be available on reasonable terms, if at all. If we are unable to obtain additional financing, we may be required to reduce the scope of, delay, or eliminate some or all of, our planned research, development and commercialization activities, which could materially harm our business. In addition, if we raise additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to products or proprietary technologies, or grant licenses on terms that are not favorable.

Our forecast of the period of time through which our financial resources will be adequate to support our operations, the costs to complete development of products and the cost to commercialize our products are forward-looking statements and involve risks and uncertainties, and actual results could vary materially and negatively as a result of a number of factors, including the factors discussed in Part I, Item 1A, *Risk Factors*, of our Annual Report on Form 10-K. We have based these estimates on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect.

The Company's acquisition of the Lap-Band product line provides incremental revenues and cash flows and does not require further product development. In order to continue the development of, and to successfully commercialize the ReShape Vest, the Company's management is currently pursuing various funding options, including seeking additional equity or debt financing as well as a strategic merger or other transaction to obtain additional funding. The Company has a long history of raising equity financing to fund its development activities; however, there can be no assurance that the Company will continue to be successful in its efforts. Should the Company be unable to obtain adequate financing in the near term, the Company's business, result of operations, liquidity and financial condition would be materially and negatively affected, and the Company would be unable to continue as a going concern. Additionally, there can be no assurance that, assuming the Company is able to strengthen its cash position, it will achieve sufficient revenue or profitable operations to continue as a going concern. The consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Because of the numerous risks and uncertainties associated with the development of medical devices, such as our ReShape Vest, we are unable to estimate the exact amounts of capital outlays and operating expenditures necessary to complete the development of the ReShape Vest or other additional products and successfully deliver a commercial product to the market. Our future capital requirements will depend on many factors, including, but not limited to, the following:

- the cost and timing of establishing sales, marketing and distribution capabilities;

- the cost of establishing clinical and commercial supplies of our ReShape Vest and any products that we may develop;
- the rate of market acceptance of our ReShape Vest and any other product candidates;
- the cost of filing and prosecuting patent applications and defending and enforcing our patent and other intellectual property rights;
- the cost of defending, in litigation or otherwise, any claims that we infringe third-party patent or other intellectual property rights;
- the effect of competing products and market developments;
- the cost of explanting clinical devices;
- the terms and timing of any collaborative, licensing or other arrangements that we may establish;
- revenue from sales of our established Lap-Band product, any revenue generated by sales of our ReShape Vest or future products;
- the scope, rate of progress, results and cost of our clinical trials and other research and development activities;
- the cost and timing of obtaining any further required regulatory approvals; and
- the extent to which we invest in products and technologies, although we currently have no commitments or agreements relating to any of these types of transactions.

#### **Critical Accounting Policies and Estimates**

The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States which require us to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the Condensed Consolidated Financial Statements and revenues and expenses during the periods reported. Actual results could differ from those estimates. Information with respect to our critical accounting policies and estimates which we believe could have the most significant effect on our reported results and require subjective or complex judgments by management is contained on pages 37-38 in Item 7, “Management's Discussion and Analysis of Financial Condition and Results of Operations,” of our Annual Report on Form 10-K for the year ended December 31, 2018. There have been no significant changes from the information discussed therein.

During the six months ended June 30, 2019 there were no material changes to our significant accounting policies which are fully described in Note 2 to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2018.

#### **Off-Balance Sheet Arrangements**

As of June 30, 2019, we did not have any off-balance sheet arrangements.

#### **Recent Accounting Pronouncements**

See Note 1 to our Condensed Consolidated Financial Statements for a discussion of recent accounting pronouncements.

## ITEM 4. CONTROLS AND PROCEDURES

### *Evaluation of Disclosure Controls and Procedures*

Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act), defines the term “disclosure controls and procedures” as those controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Based on their evaluation as of June 30, 2019, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were not effective as of June 30, 2019 for the reasons described below:

Management has determined that the Company has not maintained adequate accounting resources with a sufficient understanding of accounting principles generally accepted in the United States of America (“GAAP”) to allow the Company to identify and properly account for new complex transactions. Management has determined that this represents a material weakness in the Company’s internal control over financial reporting. As a result of this material weakness, management has identified the following additional material weakness in the Company’s internal control over financial reporting:

- The Company did not design and implement internal controls around research and development expenses paid to a Contract Resource Organization (“CRO”). This material weakness resulted in the Company not identifying that certain research and development expenses paid to the CRO in connection with the clinical trial of the ReShape Vest are required to be capitalized under GAAP and recognized into expense as the value of the capitalized asset is realized.

Notwithstanding the material weaknesses in our internal control over financial reporting, we have concluded that the consolidated financial statements and other financial information included in our annual and quarterly filings fairly present in all material respects our financial condition, results of operations and cash flows as of, and for, the periods presented.

### *Material Weaknesses Remediation Activities*

To remediate the material weaknesses in our internal control over financial reporting described above, we established transactional level controls to evaluate and monitor the accounting treatment for research and development-related costs. Remediation efforts relating to the adequacy of accounting resources with a sufficient understanding of GAAP are in process, which involve a re-evaluation of our overall staffing levels within the accounting department, evaluating the extent to which additional resources are required and what qualifications such resources must possess, and attracting and hiring those resources. We also plan to re-evaluate the trainings and ongoing professional education that is provided to, and required of, our accounting personnel. Once these processes have been in operation for a sufficient period of time for our management to conclude that the material weaknesses have been fully remediated and our internal controls over financial reporting are effective, we will consider these material weaknesses fully addressed.

### *Changes in Internal Control Over Financial Reporting*

There were no changes in our internal control over financial reporting during the quarter ended June 30, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting, other than as described below.

- Activities pertaining to our remediation efforts of material weaknesses (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act)•
- New business processes pertaining to accounting for the lap-band sales and accounts receivable

## PART II – OTHER INFORMATION

### ITEM 1. LEGAL PROCEEDINGS

*Fulfillium.* On April 20, 2017, Fulfillium, Inc. filed a complaint against ReShape Medical, Inc. (which the Company acquired in October 2017 and which is now a wholly owned subsidiary of the Company) in the U.S. District Court for the District of Delaware, which alleged misappropriation of trade secrets and infringement of two U.S. Patents (“Fulfillium I”). On July 28, 2017, ReShape Medical moved to dismiss both the trade secret claim and certain aspects of the patent infringement claim, and to transfer the litigation to the U.S. District Court for the Central District of California. On October 16, 2017, the Court granted ReShape Medical’s motion to dismiss the trade secret and willful infringement claims, and ordered the case transferred to the U.S. District Court for the Central District of California. Fulfillium twice amended its complaint, narrowing its original trade secret claim and adding further patent infringement claims and additional parties. On June 4, 2018, ReShape Medical filed a motion to dismiss the patent infringement claims for lack of standing, which the Court granted on July 5, 2018. On August 10, 2018, the Court dismissed without prejudice the trade secret claim for lack of subject matter jurisdiction and terminated the case. Fulfillium has appealed these dismissals and ReShape Medical has appealed the grant and denial of certain attorney fee awards. On July 20, 2018, Fulfillium filed a new complaint against ReShape Lifesciences, Inc. (and its wholly owned subsidiary ReShape Medical LLC) in the U.S. District Court for the Central District of California (“Fulfillium II”) reasserting the patent infringement claims asserted in Fulfillium I. On August 15, 2018, Fulfillium amended its complaint in Fulfillium II to reassert the trade secret misappropriation claim asserted in Fulfillium I against ReShape Medical LLC and others. On September 7, 2018, Fulfillium filed a complaint in California state court alleging the same trade secret misappropriation claim asserted in both Fulfillium I and Fulfillium II. On November 7, 2018, the Court dismissed the non-Company parties from Fulfillium II. On April 20, 2018, ReShape Medical filed Inter Partes Review (“IPR”) petitions with the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office (the “PTAB”) to have all claims of both of the originally asserted Fulfillium patents canceled as unpatentable over various combinations of prior art. On November 6, 2018, the PTAB denied those petitions. The parties held a mediation on April 9, 2019, but were unable to resolve the matter. The Company intends to continue to vigorously defend itself against Fulfillium’s claims. We currently are unable to estimate the losses or range of loss for these two matters.

*Alpha and Iroquois.* On July 12, 2018, Alpha Capital Anstalt (“Alpha”) filed a complaint against the Company in the U.S. District Court for the Southern District of New York. In August 2017, Alpha acquired shares of the Company’s series B convertible preferred stock and warrants to purchase shares of the Company’s common stock in an underwritten public offering. Pursuant to the terms of the series B convertible preferred stock and warrants, the conversion price of the series B convertible preferred stock and exercise price of the warrants was subject to adjustment in the case of, among other things, dilutive issuances of securities by the Company. The complaint alleged breach of contract, claiming that the Company should have adjusted the conversion price of the series B convertible preferred stock and exercise price of the warrants to not less than \$420.00 per share, rather than the \$1,575.00 per share to which the Company actually adjusted such conversion price and exercise price, in connection with its registered direct offering of series D convertible preferred stock and warrants to purchase common stock that it completed and announced in April 2018. On July 26, 2018, Iroquois Capital Investment Group, LLC and Iroquois Master Fund, Ltd. (“Iroquois”) filed a complaint against the Company in the U.S. District Court for the Southern District of New York, with substantially the same claims and seeking substantially the same relief as Alpha’s complaint described above, except that Iroquois claimed that the conversion price of the series D convertible preferred stock and exercise price of the warrants should have been adjusted to \$189.00 per share. Following a mediation held on June 20, 2019, the parties each entered into a mutually agreeable settlement agreement resolving the issues raised in the complaints filed by each Alpha and Iroquois. Pursuant to the settlement agreements, each lawsuit has been dismissed with prejudice. The terms of the settlement agreements are confidential.

Except as disclosed in the foregoing paragraphs, the Company is not currently a party to any litigation and the Company is not aware of any pending or threatened litigation against it that is reasonably possible to have a material adverse effect on the Company’s business, operating results or financial condition. The medical device industry in which the Company operates is characterized by frequent claims and litigation, including claims regarding patent and other intellectual property rights as well as improper hiring practices. As a result, the Company may be involved in various legal proceedings from time to time. Except as disclosed in the foregoing paragraphs, the Company is not currently a party to any litigation and the Company is not aware of any pending or threatened litigation against it that could have a material adverse effect on the Company’s business, operating results or financial condition. The medical device industry in which the Company operates is characterized by frequent claims and litigation, including claims regarding patent and

other intellectual property rights as well as improper hiring practices. As a result, the Company may be involved in various legal proceedings from time to time.

**ITEM 1A. RISK FACTORS**

There have been no material changes to the risk factors set forth in Item 1.A Risk Factors of our 2018 Annual Report on Form 10-K filed on May 16, 2019.

**ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

*Unregistered Sales of Equity Securities*

None.

*Uses of Proceeds from Sale of Registered Securities*

None.

*Purchases of Equity Securities*

None.

**ITEM 3. DEFAULTS UPON SENIOR SECURITIES**

None.

**ITEM 4. MINE SAFETY DISCLOSURES**

Not applicable.

**ITEM 5. OTHER INFORMATION**

None.

**ITEM 6. EXHIBITS**

<u>Exhibit No.</u>	<u>Description</u>
10.1	<a href="#">Form of Securities Purchase Agreement, dated June 13, 2019, by and between the Company and the purchasers party thereto (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 19, 2019).</a>
10.2	<a href="#">Form of Series A Warrant issued June 18, 2019 (incorporated by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 19, 2019).</a>
10.3	<a href="#">Form of Series B Warrant issued June 18, 2019 (incorporated by reference to Exhibit 10.3 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 19, 2019).</a>
10.4	<a href="#">Form of Series C Pre-Funded Warrant issued June 18, 2019 (incorporated by reference to Exhibit 10.4 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 19, 2019).</a>
10.5	<a href="#">Form of Registration Rights Agreement, dated June 18, 2019 (incorporated by reference to Exhibit 10.5 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 19, 2019).</a>
31.1**	<a href="#">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a>

<u>Exhibit No .</u>	<u>Description</u>
31.2**	<a href="#">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a>
32.1**	<a href="#">Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a>
32.2**	<a href="#">Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a>
101**	Financial statements from the Quarterly Report on Form 10-Q of the Company for the quarter ended June 30, 2019, formatted in Extensible Business Reporting Language: (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Operations, (iii) the Condensed Consolidated Statements of Stockholders' Equity, (iv) the Condensed Consolidated Statements of Cash Flows and (v) the Notes to Condensed Consolidated Financial Statements.

---

\*\* Filed herewith.



## CERTIFICATION

I, Barton P. Bandy, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of ReShape Lifesciences Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

/s/ BARTON P. BANDY

**Barton P. Bandy**  
**President and Chief Executive Officer**

Date: August 16, 2019

---

## CERTIFICATION

I, Scott P. Youngstrom certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of ReShape Lifesciences Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

/s/ SCOTT P. YOUNGSTROM

**Scott P. Youngstrom**  
**Chief Financial Officer, Senior Vice**  
**President, Finance**

Date: August 16, 2019

---



**CERTIFICATION**

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the Exchange Act), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Scott P. Youngstrom, in his capacity as Chief Financial Officer of ReShape Lifesciences Inc., hereby certifies that, to the best of his knowledge:

1. The Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2019 to which this Certification is attached as Exhibit 32.2 (the Report) fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and the results of operations of ReShape Lifesciences Inc. as of, and for, the periods covered by the Report.

By:           /s/ SCOTT P. YOUNGSTROM            
**Scott P. Youngstrom**  
**Chief Financial Officer, Senior Vice**  
**President, Finance**

Date: August 16, 2019

---

